Panacea Bio Chem's hydroxypropyl-beta-cyclodextrin research

What Panacea brings

Peptourbillon®, Panacea's formulation engine, carries a dedicated cyclodextrin classification engine: for every formulation it decides whether hydroxypropyl-beta-cyclodextrin is required, strongly suggested, optional or excluded, and in which domain it belongs — inside the freeze-dried cake or in the liquid of the second chamber. The engine's cyclodextrin rules are first-class: the ring reaches the cake only through its own dedicated resolver, never by accident.

Lyoprester®, Panacea's dual-chamber cartridge, keeps a freeze-dried cake and its liquid apart until the moment of use; Panacea's low-temperature lyophilisation preserves what the formulation was built to carry.

HW6-Piceid, Panacea's polydatin programme, already pairs the resveratrol glucoside with hydroxypropyl-beta-cyclodextrin as its wetting and delivery partner.

Which cyclodextrin, at what ratio, with which partner molecule, in which chamber and through which process — those are Panacea's secrets, held back by choice.

The research programme

1. Crystal clearance. Cyclodextrin formulations designed to dissolve the cholesterol crystals at the core of plaque.
2. Partnered complexes. The ring as the carrier of cardioprotective molecules, building on Panacea's polydatin–HPβCD work.
3. Stable, ready-to-use formats. Freeze-dried cyclodextrin formulations in the Lyoprester® dual-chamber cartridge.

The ground it stands on

Plaque regression and macrophage reprogramming in models^[1]; reduced crystal-driven inflammation in human blood^[2]; plaque regression and symptom relief reported in people^[3,4,5]; and decades of human parenteral use^[6].

Peptourbillon® is a proprietary Panacea Bio Chem platform developed and invented by Bogdan Dicoias. Its parameters are not publicly disclosed. Lyoprester® is a proprietary Panacea Bio Chem technology developed and invented by Bogdan Dicoias. Its parameters are not publicly disclosed.

Panacea Bio Chem’s cyclodextrin programme

Panacea Bio Chem works on molecules and on everything around them. Compounds are synthesised, tested and experimented with in-house, carried through the company's own analytical gate, and taken into clinical development — the route the NBetaX™ platform is taking with N-BX01, its lead endometriosis candidate. n-bx.com

Panacea Bio Chem owns this thesis: cholesterol already locked inside arterial plaque can be taken out again, with a cyclodextrin built into the right formulation. The lead candidate is hydroxypropyl-beta-cyclodextrin, the soluble ring that reaches the plaque.

The capability ladder

1. Peptourbillon® — the formulation engine, with its dedicated cyclodextrin classification: where the ring belongs, and when it must stay out.
2. Lyoprester® — the dual-chamber cartridge that keeps the freeze-dried formulation sealed and stable until use.
3. Low-temperature lyophilisation — the cold process that preserves every component of the cake.
4. HW6-Piceid — the polydatin–HPβCD inclusion work, the programme’s proof that the ring can carry a cardioprotective partner.

Each rung was invented by Bogdan Dicoias. A cyclodextrin is only as good as the formulation around it. Panacea designs the formulation, prepares it, tests it, keeps it stable in its own container and carries candidates into clinical development — which is why this programme belongs here and not in a catalogue.

The translational pathway

Each stage illuminates as a real milestone is reached; the stages ahead remain outlined.

Which cyclodextrin, at what ratio, with which partner molecule, in which chamber and through which process — those are Panacea’s own, held back by choice.

The first goal is a stable cyclodextrin formulation that dissolves the cholesterol in plaque. The next is a medicine. The ultimate goal is the end of atherosclerotic heart disease.

Trending in the field

References

1. Zimmer S, Grebe A, Bakke SS, Bode N, Halvorsen B, Ulas T, et al.. Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming. Sci Transl Med 2016;8(333):333ra50. PMID 27053774
2. Bakke SS, Aune MH, Niyonzima N, Pilely K, Ryan L, Skjelland M, et al.. Cyclodextrin Reduces Cholesterol Crystal-Induced Inflammation by Modulating Complement Activation. J Immunol 2017;199(8):2910-2920. PMID 28855312
3. Hodgetts K, Howes L, Fang YY, Song ZM. 2-Hydroxypropyl-β-Cyclodextrin Induces Rapid Regression of Atherosclerotic Plaque and Reduces Hyperlipidaemia in Adult with Cardiovascular Disease. Cardiol Res Cardiovasc Med 2024;9:261. doi.org/10.29011/2575-7083.100261
4. Hodgetts K, Roberts JC, Howes LG. Cyclodextrin Therapy for Atherosclerotic Cardiovascular Disease: A Case Series on Plaque Regression and Symptomatic Improvement. Cardiol Res Cardiovasc Med 2025;10:284. doi.org/10.29011/2575-7083.100284
5. Hodgetts K, Roberts J. Regression of Atherosclerotic Plaque Via High-Viscosity 2-Hydroxypropyl-β-Cyclodextrin (Cavadex): A Multi-Center Retrospective Case Series. Cardiol Res Cardiovasc Med 2026;11:292. doi.org/10.29011/2575-7083.100292
6. Carpenter TO, Gerloczy A, Pitha J. Safety of parenteral hydroxypropyl beta-cyclodextrin. J Pharm Sci 1995;84(2):222-5. PMID 7738806